Advanced Search
MyIDEAS: Login to save this paper or follow this series

The Effect of New Drugs on Mortality from Rare Diseases and HIV


Author Info

  • Frank R. Lichtenberg


I investigate the effect of large increases in the number of drugs available to treat rare diseases and HIV on mortality associated with them. Mortality from both diseases declined dramatically following increases in drug approvals. Before the Orphan Drug Act went into effect (between 1979 and 1984), mortality from rare diseases grew at the same rate as mortality from other diseases. In contrast, during the next five years, mortality from rare diseases grew more slowly than mortality from other diseases. I estimate that one additional orphan drug approval in year t prevents 211 deaths in year t+1 and ultimately prevents 499 deaths, and that about 108 thousand deaths from rare diseases will ultimately be prevented by all of the 216 orphan drugs tha t have been approved since 1983. Deaths are more closely related to the number of orphan product designations (which include experimental drugs) than they are to the number of approvals. Consistent with previous patient- level studies of HIV, I find that new drugs played a key role in the post-1995 decline in HIV mortality. I estimate that one additional HIV drug approval in year t prevents 5986 HIV deaths in year t+1 and ultimately prevents 33,819 HIV deaths. HIV drug approvals have reduced mortality both directly and indirectly (via increased drug consumption). HIV mortality depends on both the quality and the quantity of medications consumed, and new drug approvals have a sizeable impact on drug consumption: one additional HIV drug approval in year t results in 1.2 million additional HIV drug units consumed in year t+1 and ultimately result in 3.6 million additional HIV drug units consumed.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL:
Download Restriction: no

Bibliographic Info

Paper provided by National Bureau of Economic Research, Inc in its series NBER Working Papers with number 8677.

as in new window
Date of creation: Dec 2001
Date of revision:
Handle: RePEc:nbr:nberwo:8677

Note: HC
Contact details of provider:
Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Phone: 617-868-3900
Web page:
More information through EDIRC

Related research


Find related papers by JEL classification:

This paper has been announced in the following NEP Reports:


No references listed on IDEAS
You can help add them by filling out this form.


Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as in new window

Cited by:
  1. Rodrigo Cerda, 2007. "Endogenous innovations in the pharmaceutical industry," Journal of Evolutionary Economics, Springer, vol. 17(4), pages 473-515, August.
  2. Shin-Yun Wang & Chih-Chiang Hwang, 2011. "Application of options to the pharmaceutical markets: The solutions of corruption and counterfeit drugs in emerging markets," International Journal of Accounting and Information Management, Emerald Group Publishing, vol. 19(2), pages 169-181, June.


This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.


Access and download statistics


When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:8677. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.